Zobrazeno 1 - 10
of 21
pro vyhledávání: '"V V Ryazhenov"'
Autor:
V V Ryazhenov
Publikováno v:
Современная онкология, Vol 19, Iss 1, Pp 54-57 (2017)
This article deals with the pharmacoeconomic comparative analysis of different strategies of pharmacotherapy using low-molecular-weight tyrosine kinase inhibitors (afatinib and gefitinib) in patients with non-small cell lung cancer associated with mu
Externí odkaz:
https://doaj.org/article/d24be327f8b944e8a2200d9be6a37b1e
Autor:
V V Ryazhenov, S G Gorokhova
Publikováno v:
Современная онкология, Vol 18, Iss 3, Pp 84-89 (2016)
The article presents the results of pharmacoeconomic study concerning different approaches to treat patients with non-small cell lung cancer and mutations in the EGFR gene. We have compared two common therapy regimens, which are used in routine pract
Externí odkaz:
https://doaj.org/article/0613dde7b6df45169b46427d78abb07a
Autor:
V V Ryazhenov, S G Gorokhova
Publikováno v:
Современная онкология, Vol 14, Iss 3, Pp 41-44 (2012)
Externí odkaz:
https://doaj.org/article/7b4cdd92cce94839b09e8c67ca4c6e32
Autor:
V V Ryazhenov, S G Gorokhova
Publikováno v:
Современная онкология, Vol 13, Iss 3, Pp 19-22 (2011)
Externí odkaz:
https://doaj.org/article/806e641de2e54d6da0e44a04b8a135ca
Publikováno v:
Фармакоэкономика, Vol 17, Iss 1, Pp 5-21 (2024)
Objective: to assess clinical and economic implications of adding daratumumab (Dara) to the “lenalidomide + dexamethasone” (Rd) treatment program in early lines of therapy for patients with multiple myeloma (MM) ineligible for high-dose chemother
Externí odkaz:
https://doaj.org/article/a71101750599473695e4e01404b9c110
Autor:
O. I. Ivakhnenko, V. V. Ryazhenov, E. A. Maksimkina, V. S. Fisenko, O. V. Savoskin, M. M. Kuznetsova
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 12, Iss 1, Pp 15-31 (2024)
The accessibility and pharmaceutical care coverage are linked to political, economic and managerial decisions. That fact necessitates the evaluation of the state programs results in the field of the drug provision.The aim of the work was to assess th
Externí odkaz:
https://doaj.org/article/a5a18ee5e8ca4d95a6d3fb4d81907f49
Autor:
V V Ryazhenov, S G Gorokhova
Publikováno v:
Современная онкология, Vol 14, Iss 3, Pp 57-59 (2012)
Externí odkaz:
https://doaj.org/article/a2c419dca54c48f294a598813287317c
Autor:
A. V. Alekhin, T. N. Erivantseva, V. V. Ryazhenov, N. N. Lyskov, N. A. Alekhina, M. M. Kuznetsova
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 2, Pp 161-172 (2023)
The aim of the work was to study the legal aspects of the legislative regulation for manufacturing medicines in a pharmacy organization.Materials and methods. Databases of ConsultantPlus, Cyberleninka, Food and Drug Administration (FDA), European Med
Externí odkaz:
https://doaj.org/article/7457954f912b42b8adab0c2ba2fcaae5
Publikováno v:
Регуляторные исследования и экспертиза лекарственных средств, Vol 0, Iss 1, Pp 56-59 (2022)
RETRACTED ARTICLE«Budget impact analysis» method gives an opportunity to assess the expected costs of the budget for the phases before and after the introduction of new technology and/or a combination of technologies in certain nosology. The result
Externí odkaz:
https://doaj.org/article/34fa8f32cf70464b8619dc582718cd69
Autor:
V. V. Ryazhenov, S. G. Gorokhova
Publikováno v:
Вестник трансплантологии и искусственных органов, Vol 13, Iss 3, Pp 20-25 (2011)
CMV infection is a major problem in kidney transplantation patients. Valcyte, Cimevene are the first line thera- py of CMV infection. This pharmacoeconomic analysis shown economic benefits of Valcyte prophylaxis tactic compare preemptive strategy.
Externí odkaz:
https://doaj.org/article/aa02b547067446aa921e2e6d942db6ae